Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Enterprise Value (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Enterprise Value for 10 consecutive years, with -$414.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 31.34% to -$414.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$414.0 million, a 31.34% increase, with the full-year FY2025 number at -$414.0 million, up 31.34% from a year prior.
  • Enterprise Value was -$414.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from -$195.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$85.8 million in Q1 2023 to a low of -$965.4 million in Q1 2021.
  • A 5-year average of -$445.8 million and a median of -$428.0 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: soared 85.67% in 2023, then crashed 648.41% in 2024.
  • Ultragenyx Pharmaceutical's Enterprise Value stood at -$740.2 million in 2021, then decreased by 1.02% to -$747.8 million in 2022, then rose by 22.75% to -$577.6 million in 2023, then dropped by 4.39% to -$603.0 million in 2024, then surged by 31.34% to -$414.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Enterprise Value are -$414.0 million (Q4 2025), -$195.5 million (Q3 2025), and -$169.3 million (Q2 2025).